The results were presented at the 2018 American Society of Clinical Oncology's Genitourinary Cancers Symposium (ASCO GU) in a poster presentation titled "Tivozanib combined with nivolumab: Phase Ib/II study in metastatic renal cell carcinoma."
The Phase 1/2 multicenter study has enrolled a total of 27 patients. The Phase 2 portion of the study was designed to assess the safety, tolerability, and anti-tumor activity of the full dose and schedule of PO tivozanib (1.5 mg/QD for 21 days followed by a 7-day rest period), as established in the Phase 1 portion of the study, in combination with IV nivolumab (240 mg every 2 weeks).
The combination was generally well tolerated. Treatment-related Grade 3/4 adverse events occurred in 44% of patients, the most common of which was hypertension.
Tivozanib (Fotivda) is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor of all three VEGF receptors.
It is designed to optimize VEGF blockade while minimizing off-target toxicities, and has been shown to significantly reduce regulatory T-cell production in preclinical models. Fotivda has been investigated in several tumors types, including renal cell, hepatocellular, colorectal, and breast cancers.
EUSA Pharma focuses on oncology and oncology supportive care. The company has commercial operations in the US and Europe, and a wider distribution network in approximately 40 countries around the world.
Aveo Oncology is dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need.
The company is focused on development and commercialisation of its lead candidate tivozanib as a treatment for renal cell carcinoma and other cancers in North America, and is leveraging multiple partnerships to develop and commercialise tivozanib in oncology indications outside of North America, and at progressing its pipeline of novel therapeutic candidates in cancer and cachexia.
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories